Prevention of Glomerular Damage with Pharmacologic Agents

  • John P. Hayslett


Histopathologic lesions in the glomerulus may result in increased protein excretion and/or a reduction in glomerular filtration rate, depending on the type and severity of the pattern of injury. In the absence of necrosis and replacement of normal structure with sclerosis it is usually assumed that there is a potential for reversibility. During the past 30 years a variety of pharmacologic agents have been employed clinically in the hope of hastening recovery by inducing resolution of the injury reaction or preventing progressive glomerular sclerosis with further decline in renal function. Since most forms of acquired glomerulopathy are presumably due to immunologic processes, therapeutic modalities have often been employed on the basis of their known or assumed action to alter immunologic responses, or their action to reduce inflammation or inhibit intravascular clotting. Despite this long experience, however, the pharmacologic basis for treating various patterns of glomerular injury remains empirical. Selection of individual pharmacologic agents for their effect on reversing or stabilizing different types of glomerular lesions is usually based on empirical clinical evidence that the cause of changes in renal function of treated patients is or is not more favorable than observed in nontreated patients. In some instances serial renal biopsies have been performed that provide information on changes in the underlying renal histopathologic lesion during the course of treatment.


Lupus Nephritis Membranous Nephropathy Glomerular Injury Crescentic Glomerulonephritis Glomerular Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Siegel NJ, Goldberg B, Krassner LS, et al: Long-term followup of children with steroid-responsive nephrotic syndrome. J Pediat 81: 251 - 258, 1972.PubMedCrossRefGoogle Scholar
  2. 2.
    Barratt TM, Soothill JF: Controlled trial of cyclophosyphamide in steroid-sensitive relapsing nephrotic syndrome of children. Lancet 2: 479 - 482, 1970.PubMedCrossRefGoogle Scholar
  3. 3.
    Arieff AI, Piggera WF: Rapidly progressive glomerulonephritis treated with anticoagulants. Arch Inter Med 129: 77 - 84, 1972.CrossRefGoogle Scholar
  4. 4.
    Collaborative Study of the Adult Idiopathic Nephrotic Syndrome: A controlled study of short-term predinsone treatment in adults with membranous nephropathy. N Engl J Med 301: 1301 - 1306, 1979.CrossRefGoogle Scholar
  5. 5.
    Fauci AS, Katz P, Haynes BF, et al: Cyclophosphamide therapy of severe necrotizing vasculities. N Engl J Med 301: 235 - 238, 1979.PubMedCrossRefGoogle Scholar
  6. 6.
    NIH conference, Wolff SM (moderator): Wegener’s granulomatosis. Ann Intern Med 81: 513 - 525, 1979.Google Scholar
  7. 7.
    Novack SN, Pearson CM: Cyclophosphamide therapy in Wegener’s granulomatosis. N Engl J Med 284: 938 - 942, 1971.PubMedCrossRefGoogle Scholar
  8. 8.
    Donadio JV, Holley KE, Wagoner RD, et al: Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 77: 829 - 835, 1972.PubMedGoogle Scholar
  9. 9.
    Decker JL., Kluppel JH, Plotz PN, et al: Cyclophosphamide or azathioprine in lupus glomerulonephritis. Ann Intern Med 83: 606 - 615, 1975.PubMedGoogle Scholar
  10. 10.
    Donadio JV, Holley KE, Ferguson RN, et al: Treatment of diffuse proliferative lupus nephritis with prednisone and combined predinsone and cyclophosphamide. N Engl J Med 299: 1151 - 1155, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Hecht B, Siegel NJ, Adler M, et al: Prognostic indices of lupus nephritis. Medicine 55: 163181, 1976.Google Scholar
  12. 12.
    Pollak VE, Pirani CL, Kark RM: Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 57: 495 - 511, 1961.PubMedGoogle Scholar
  13. 13.
    Mahajan SK, Ordonez NC, Feitelson PJ, et al: Lupus nephropathy without clinical renal involvement. Medicine 56: 493 - 501, 1977.PubMedCrossRefGoogle Scholar
  14. 14.
    Appel GB, Silva FG, Pirani CL, et al: Renal involvement in systemic lupus erythematosus (SLE). Medicine 57: 371 - 410, 1978.PubMedCrossRefGoogle Scholar
  15. 15.
    Beirne GJ, Wagnlid JP, Zimmerman SW, et al: Idiopathic crescentic glomerulonephritis. Medicine 56: 349 - 381, 1977.PubMedCrossRefGoogle Scholar
  16. 16.
    Whiteworth VA, Morel-Maroger L, Megnon F, et al: The significance of extracapillary proliferation. Clinicopathological review of 60 patients. Nephron 16: 1 - 19, 1976.CrossRefGoogle Scholar
  17. 17.
    Stilmant NM, Bolton WK, Sturgill BC, et al: Crescentic glomerulonephritis without immune deposits: Clinicopathologic features. Kidney Inter 15: 184 - 195, 1979.CrossRefGoogle Scholar
  18. 18.
    Bolton WK, Couser WC: Intravenous pulse methyleprednisolone therapy of acute crescentic rapidly progressive glomerulonephritis. Am J Med 66: 995 - 502, 1979.CrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1982

Authors and Affiliations

  • John P. Hayslett
    • 1
  1. 1.Section of Nephrology, and Department of Internal MedicineYale University School of MedicineNew HavenUSA

Personalised recommendations